Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 13/20 | 0.50 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17456308 | 0.88 | CYP11B2 (0.49) | CYP11B2HCAR1 | |
| SCHEMBL31307615 | 0.84 | CYP11B2 (0.49) | CYP11B2HCAR1 | |
| SCHEMBL17456265 | 0.80 | CYP11B2 (0.58) | CYP11B2 | |
| SCHEMBL25584680 | 0.80 | CYP11B2 (0.50) | CYP11B2 | |
| Vicadrostat SCHEMBL17456323 | 0.75 | CYP11B2 (0.64) | CYP11B2 | |
| SCHEMBL17456272 | 0.74 | CYP11B2 (0.61) | CYP11B2 | |
| SCHEMBL17456293 | 0.73 | CYP11B2 (0.54) | CYP11B2HCAR1 | |
| SCHEMBL25584370 | 0.73 | CYP11B2 (0.54) | CYP11B2HCAR1 | |
| SCHEMBL17456319 | 0.71 | CYP11B2 (0.64) | CYP11B2 | |
| SCHEMBL25584182 | 0.71 | CYP11B2 (0.64) | CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181538-A1 | ALDOSTERONE SYNTHASE INHIBITORS FOR TREATING CHRONIC KIDNEY DISEASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181538-A1 | ALDOSTERONE SYNTHASE INHIBITORS FOR TREATING CHRONIC KIDNEY DISEASE | SLC5A2, SLC5A1, REN | CYP11B2 10/4885HCAR1 656/4885RECQL 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.